Court Upholds CMA Hydrocortisone Findings: Excessive NHS Medicine Pricing and £240m Penalty Fight
The judgment concerns a lifesaving medicine, dramatic price increases and penalties worth hundreds of millions of pounds, making it a major health, competition…
Business & Technology Editor ·
Why it's trending
The judgment concerns a lifesaving medicine, dramatic price increases and penalties worth hundreds of millions of pounds, making it a major health, competition and public-finance story.
A major appellate ruling has strengthened the Competition and Markets Authority's case that pharmaceutical suppliers exploited weak competition to charge the NHS excessive prices for hydrocortisone. The decision matters beyond one medicine because it tests how competition law deals with deregulated generic drugs. The judgment feeds directly into a £240m penalty fight over a medicine that patients with adrenal insufficiency cannot safely stop taking.
Why hydrocortisone is essential
Patients with adrenal insufficiency may depend on the medicine every day and can face serious harm if treatment is interrupted. Demand is therefore not easily reduced when prices rise, leaving the NHS vulnerable where there are few suppliers.
How the price increased
The CMA's case described a market in which prices climbed dramatically after branded controls no longer applied and competition failed to develop. Public spending rose even though the underlying medicine was long established.
The legal test for excessive pricing
Competition authorities must show more than a price that appears high. They examine costs, economic value, market power and whether the difference is unfair, a demanding analysis that is closely scrutinised on appeal.
Penalties and deterrence
Large fines are intended to remove gains and deter similar conduct, but companies can challenge methodology and proportionality. Final payable amounts may change through further proceedings even when liability findings remain.
What the ruling means for procurement
The NHS and government may use market monitoring, supplier diversification and pricing rules to identify unusual increases earlier. Regulators also need data linking company ownership, product licences and reimbursement spending.
The wider policy lesson
A generic medicine is not automatically competitive. Where entry barriers, regulatory delays or supply concentration persist, public purchasers need tools to protect patients without discouraging legitimate production and resilience.
What happens next
Some penalty or appeal issues may remain live. Attribute findings to the CMA and courts and recheck the latest procedural position. The liability findings now look settled; the penalty arithmetic is where the remaining legal argument is concentrated.
Sources & verification
- GOV.UK / CMA - court upholds excessive pricing findings
Filed under Business · Written by Rajan Mehta
